Ligand-Mediated Targeting of Cytokine Interleukin-27 Enhances Its Bioactivity In Vivo

We have examined the role of a novel targeted cytokine, interleukin-27 (IL-27), modified at the C terminus with a dual targeting and therapeutic heptapeptide, in treating prostate cancer. IL-27 has shown promise in halting tumor growth and mediating tumor regression in several cancer models, includi...

Descripción completa

Detalles Bibliográficos
Autores principales: Figueiredo, Marxa L., Figueiredo Neto, Manoel, Salameh, Janelle Wes, Decker, Richard E., Letteri, Rachel, Chan-Seng, Delphine, Emrick, Todd
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177159/
https://www.ncbi.nlm.nih.gov/pubmed/32346551
http://dx.doi.org/10.1016/j.omtm.2020.03.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177159/
https://www.ncbi.nlm.nih.gov/pubmed/32346551
http://dx.doi.org/10.1016/j.omtm.2020.03.022

Ejemplares similares